Prostate Adenocarcinoma
Conditions
Brief summary
Stereotactic ablative Body Radiotherapy (SBRT) is an advanced radiation technique that allows for precise delivery of higher radiation doses in fewer treatment sessions, resulting in a shorter overall treatment duration. The available clinical evidence suggests that SBRT is highly effective in controlling localized prostate cancer (PCa) with acceptable side effects. On the other side, dose escalation is a commonly employed strategy in radiotherapy for prostate cancer. Recent studies have confirmed a dose-response relationship, demonstrating improved biochemical control with focal dose escalation to the identified dominant intraprostatic lesion (DIL) on multiparametric magnetic resonance imaging (mpMRI) of the prostate. The hypothesis of this study is that the combination prostate SBRT with focal dose intensification on the DIL with preservation of the prostatic urethra, would lead to a higher probability of local control without a significant increase in toxicity compared to standard clinical practice. This is a prospective single-arm phase II study designed to evaluate the effectiveness, safety and impact on quality of life of focal dose intensification using SBRT technology and extreme hypofractionated radiotherapy.
Interventions
RADIATIONProstate SBRT (stereotactic body radiation therapy) with focal boost
* Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions of 7.25 Gy to the entire prostate (including seminal vesicles) using VMAT * mpMRI defined DIL was simultaneously boosted up to 50 Gy in 5 sessions to the mpMRI identified DIL. * Additional urethra and bladder trigone sparing constrains * Daily IGRT with cone beam CT and intrafraction gold-seeds fiducial tracking
Sponsors
Almudena Zapatero
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Single group assignment
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed adenocarcinoma of the prostate * Primary localized PCa, cN0 and cM0, intermediate or high-risk disease according to NCCN 2023 * Signed written informed consent for this study * T2-T3a clinical stage with visible DIL on mpMRI * ECOG 0-1 * Desirable prostate volume (not mandatory) \< 80 cc or \> 80 cc if urinary function is preserved and dosimetrically feasible * IPSS ≤ 18 (International Prostate Symptom Score)
Exclusion criteria
* Unresolved previous prostatitis, symptomatic urethral stenosis * Bilateral hip prosthesis * T3b-4 clinical stage or N1 * M1 (presence of distant metastases) * Previous surgery at the prostate level (Transurethral Resection of the Prostate) within the last 6 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Biochemical progression-free survival | 3 years | Biochemical progression as Phoenix definition (PSA nadir +2 ng/ml) |
| Local control | 12 months | Disappearance of suspicious image on mpMRI. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and severity of late urinary treatment-related adverse events graded according to CTCAE (Common Terminology Criteria for Adverse Events) v5.0 scale | 2 years | Every urinary event occurring after 3 months from treatment completion will be defined as late event. All adverse events will be recorded and graded according to CTCA V5.0 scale (graded from 0-5 with greater values representing worse outcomes) |
| Incidence and severity of acute urinary treatment-related adverse events graded according to CTCAE (Common Terminology Criteria for Adverse Events) v5.0 scale | 90 days | Every urinary event occurring within 3 months from treatment completion will be defined as acute event. All adverse events will be recorded and graded according to CTCA V5.0 scale (graded from 0-5 with greater values representing worse outcomes) |
| Patient reported outcomes and quality of life assessment | 2 years | Impact on Quality of life affecting the genitourinary, gastrointestinal, sexual and hormonal domains using the EPIC-26 short form (International Prostate Symptom Score (IPSS) and Expanded Prostate Index Composite-26 |
| Incidence and severity of late rectal treatment-related adverse events graded according to CTCAE (Common Terminology Criteria for Adverse Events) v5.0 scale | 2 years | Every rectal event occurring after 3 months from treatment completion will be defined as late event. All adverse events will be recorded and graded according to CTCA V5.0 scale (graded from 0-5 with greater values representing worse outcomes) |
| Incidence and severity of acute rectal treatment-related adverse events graded according to CTCAE (Common Terminology Criteria for Adverse Events) v5.0 scale | 90 days | Every rectal event occurring within 3 months from treatment completion will be defined as acute event. All adverse events will be recorded and graded according to CTCA V5.0 scale (graded from 0-5 with greater values representing worse outcomes) |
Countries
Spain
Contacts
Primary ContactAlmudena Zapatero, PhD
Outcome results
None listed